DiaMedica Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $24.6M | $19.1M | $13.1M | $7.8M | $8.8M |
| Operating expenses | $34.4M | $26.7M | $21.3M | $14.0M | $13.6M |
| Operating income | -$34.4M | -$26.7M | -$21.3M | -$14.0M | -$13.6M |
| Pretax income | -$32.7M | -$24.4M | -$19.3M | -$13.6M | -$13.6M |
| Income tax expense | $28,000 | $30,000 | $43,000 | $28,000 | $28,000 |
| Net income | -$32.8M | -$24.4M | -$19.4M | -$13.7M | -$13.6M |
| Balance Sheet | |||||
| Cash and equivalents | $15.6M | $3.0M | $4.5M | $4.7M | $4.7M |
| Current assets | $60.6M | $44.6M | $53.7M | $33.8M | $45.4M |
| Total assets | $61.4M | $46.3M | $54.2M | $34.4M | $45.6M |
| Current liabilities | $5.1M | $5.4M | $2.8M | $2.2M | $1.5M |
| Stockholders' equity | $56.1M | $40.7M | $51.1M | $31.8M | $44.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$29.1M | -$22.1M | -$18.7M | -$11.5M | -$12.3M |
| Depreciation and amortization | $43,000 | $39,000 | $30,000 | $25,000 | $24,000 |
| Stock-based compensation | $3.8M | $2.1M | $1.7M | $1.5M | $1.6M |
| Capital expenditure | $40,000 | $25,000 | $24,000 | $81,000 | $22,000 |
| Free cash flow | -$29.1M | -$22.1M | -$18.8M | -$11.6M | -$12.3M |
Shares outstanding 53.9M · Free float 42.6%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.